BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

452 related articles for article (PubMed ID: 12011769)

  • 1. Relationship of the BCR gene breakpoint and the type of BCR/ABL transcript to clinical course, prognostic indexes and survival in patients with chronic myeloid leukemia.
    Prejzner W
    Med Sci Monit; 2002 May; 8(5):BR193-7. PubMed ID: 12011769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia.
    Adler R; Viehmann S; Kuhlisch E; Martiniak Y; Röttgers S; Harbott J; Suttorp M
    Eur J Haematol; 2009 Feb; 82(2):112-8. PubMed ID: 19067742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study on relationship between different bcr/abl fusion transcripts and clinical manifestations in chronic myeloid leukemia].
    Qin YZ; Liu YR; Li JL; Wang H; Chang Y; Fu JY; Ruan GR; Qiu JY; Lu DP; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):347-50. PubMed ID: 12941187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].
    Xing W; Gu BW; Zhu YM; Jiang CL; Zhao RH; Wang AH; Sun HP; Li JM; Shen ZX; Chen Z; Chen SJ
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):453-7. PubMed ID: 15854550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.
    Yaghmaie M; Ghaffari SH; Ghavamzadeh A; Alimoghaddam K; Jahani M; Mousavi SA; Irvani M; Bahar B; Bibordi I
    Arch Iran Med; 2008 May; 11(3):247-51. PubMed ID: 18426313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia.
    Kim DH; Popradi G; Sriharsha L; Kamel-Reid S; Chang H; Messner HA; Lipton JH
    Cancer; 2008 Aug; 113(4):772-81. PubMed ID: 18543309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Imatinib mesylate in chronic myeloid leukemia patients with variant BCR-ABL fusion transcripts.
    Sharma P; Kumar L; Mohanty S; Kochupillai V
    Ann Hematol; 2010 Mar; 89(3):241-7. PubMed ID: 19714331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11).
    Mundhada S; Luthra R; Cano P
    BMC Cancer; 2004 Jun; 4():25. PubMed ID: 15202948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of BCR-ABL transcript types in Korean CML patients using a newly developed multiplex RT-PCR.
    Goh HG; Hwang JY; Kim SH; Lee YH; Kim YL; Kim DW
    Transl Res; 2006 Nov; 148(5):249-56. PubMed ID: 17145570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of BCR/ABL variants in chronic myeloid leukemia patients using multiplex RT-PCR.
    Bennour A; Ouahchi I; Moez M; Elloumi M; Khelif A; Saad A; Sennana H
    Clin Lab; 2012; 58(5-6):433-9. PubMed ID: 22783572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additional chromosomal abnormalities and variability of BCR breakpoints in Philadelphia chromosome/BCR-ABL-positive acute lymphoblastic leukemia in Taiwan.
    Ko BS; Tang JL; Lee FY; Liu MC; Tsai W; Chen YC; Wang CH; Sheng MC; Lin DT; Lin KH; Tien HF
    Am J Hematol; 2002 Dec; 71(4):291-9. PubMed ID: 12447959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alu and translisin recognition site sequences flanking translocation sites in a novel type of chimeric bcr-abl transcript suggest a possible general mechanism for bcr-abl breakpoints.
    Martinelli G; Terragna C; Amabile M; Montefusco V; Testoni N; Ottaviani E; de Vivo A; Mianulli A; Saglio G; Tura S
    Haematologica; 2000 Jan; 85(1):40-6. PubMed ID: 10629590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A relationship between the breakpoint of the bcr gene and some hematologic parameters in patients with chronic myelogenous leukemia].
    Seferyńska I; Brojer E; Sankowska M; Majewski M; Maj S
    Acta Haematol Pol; 1995; 26(4):385-91. PubMed ID: 8571740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3.
    Liu LG; Tanaka H; Ito K; Kyo T; Ito T; Kimura A
    Am J Hematol; 2003 Dec; 74(4):268-72. PubMed ID: 14635208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.
    de Lemos JA; de Oliveira CM; Scerni AC; Bentes AQ; Beltrão AC; Bentes IR; Azevedo TC; Maradei-Pereira LM
    Genet Mol Res; 2005 Dec; 4(4):803-11. PubMed ID: 16475128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia.
    Onida F; Ball G; Kantarjian HM; Smith TL; Glassman A; Albitar M; Scappini B; Rios MB; Keating MJ; Beran M
    Cancer; 2002 Oct; 95(8):1673-84. PubMed ID: 12365015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular profiling of chronic myeloid leukemia in eastern India.
    Mondal BC; Bandyopadhyay A; Majumdar S; Mukhopadhyay A; Chandra S; Chaudhuri U; Chakrabarti P; Bhattacharyya S; Dasgupta UB
    Am J Hematol; 2006 Nov; 81(11):845-9. PubMed ID: 16888785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of amplified BCR/ABL fusion genes into the short arm of chromosome 17 as a novel mechanism of disease progression in chronic myeloid leukemia.
    Metzke-Heidemann S; Harder L; Gesk S; Schoch R; Jenisch S; Grote W; Siebert R; Schlegelberger B
    Genes Chromosomes Cancer; 2001 May; 31(1):10-4. PubMed ID: 11284030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
    Press RD; Galderisi C; Yang R; Rempfer C; Willis SG; Mauro MJ; Druker BJ; Deininger MW
    Clin Cancer Res; 2007 Oct; 13(20):6136-43. PubMed ID: 17947479
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.